BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, April 14, 2026
Home » Topics » Regulatory » Patents

Patents
Patents RSS Feed RSS

Cancer

DYRK1A inhibitors revealed in Biosplice Therapeutics patent

May 8, 2023
Biosplice Therapeutics Inc. has prepared and tested pyrrolo[2,1-F][1,2,4]triazines derivatives acting as dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitors and reported to be useful for the treatment of cancer, diabetes and neurological disorders.
Read More
Cardiovascular

Vasa Therapeutics patents new matrix metalloproteinase inhibitors for heart failure

May 8, 2023
Research at Vasa Therapeutics Sp zoo has led to the identification of diazabicyclooctane derivatives acting as matrix metalloproteinase (MMP) inhibitors and thus reported to be useful for the treatment of heart failure.
Read More
Neurology/Psychiatric

Kyonggi University patent describes new benzodiazepines for diabetic neuropathy

May 8, 2023
New optically active benzodiazepines have been reported in a recent Kyonggi University patent as potentially useful for the treatment of diabetic neuropathy.
Read More
Cancer

Tango Therapeutics reports development of new EHMT1 and EHMT2 inhibitors

May 8, 2023
Tango Therapeutics Inc. has patented histone-lysine N-methyltransferase EHMT1 (H3-K9-HMTase 5; GLP) and/or EHMT2 inhibitors reported to be useful for the treatment of cancer, sickle cell disease and β-thalassemia.
Read More

BioWorld MedTech Patent Highlights: Week 17

From Current Patent Gazette
May 5, 2023
BioWorld MedTech presents Patent Highlights, an excerpt of the most important med-tech patents from this week's Cortellis Patents Gazette.
Read More
Neurology/Psychiatric

Biosplice Therapeutics discovers new DYRK1A inhibitors

May 5, 2023
Biosplice Therapeutics Inc. has described 1H-pyrrolo[2,3-b]pyridines acting as dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A) inhibitors reported to be useful for the treatment of cancer, diabetes and neurological disorders.
Read More
Dermatologic

Gossamer Bio presents new non-receptor tyrosine-protein kinase TYK2 inhibitors

May 5, 2023
Gossamer Bio Inc. has divulged trisubstituted pyridines acting as non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of asthma, atopic dermatitis, contact dermatitis, inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis and allergic rhinitis, among others.
Read More
Cancer

Stemline Therapeutics describes new RET mutant inhibitors for cancer

May 5, 2023
Stemline Therapeutics Inc. has identified proto-oncogene tyrosine-protein kinase receptor Ret (RET; CDHF12; PTC) (mutant) inhibitors reported to be useful for the treatment of cancer.
Read More
Neurology/Psychiatric

Roche divulges new GABA-A receptor γ1 subunit PAMs

May 5, 2023
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized GABA-A receptor γ1 subunit positive allosteric modulators (PAMs) reported to be useful for the treatment of cognitive and neurological disorders.
Read More
Cancer

Philochem patents new radiolabeled FAP ligands

May 5, 2023
Philochem AG has disclosed conjugates comprising fibroblast activation protein α (FAP) ligands covalently linked to radiolabeled payloads through a linker. They are reported to be useful for the diagnosis of atherosclerosis, cancer, fibrosis, inflammation and keloids.
Read More
Previous 1 2 … 385 386 387 388 389 390 391 392 393 … 3801 3802 Next

Popular Stories

  • Today's news in brief

    BioWorld
  • MMP inhibitors divulged in Accure Therapeutics patent

    BioWorld Science
    Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 14, 2026
  • MSD discloses new HCN1/2 blockers

    BioWorld Science
    Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
  • Cancer cell in the cross-hairs

    Selective CBL-B inhibitor with improved safety profile disclosed

    BioWorld Science
    CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing